Interview with Ali Akyildiz, General Manager, IMS Health Turkey
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
IMS started to operate in Turkey through some other local companies in the late 60s. The first report was published in 1968. Since the inception of the local entity in 1990, it has grown significantly serving both local and multinational clients by providing information, technology solutions and professional services including consulting. Our information panel covers over 99% of the market in terms of pharmaceutical sales data and accepted as a gold standard in the industry. Our consulting team consists of 20 professional consultants and acting as a hub for Middle East to support our clients in solving their problems in portfolio strategy, market entry, mergers & acquisitions and commercial effectiveness.
Currently, IMS Turkey is serving more than 150 clients in these areas with about 140 professionals with our recent Cegedim acquisition.
Contact Details
Gazeteciler Mahallesi
Yazarlar Sokak – No. 8, 34394 Esentepe – Sisli
Istanbul
Turkey
Tel: +90 212 355 57 00
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
Evren Özlü, General Manager of Turkey and Sub-Saharan Africa at Boehringer Ingelheim, discusses the company’s double-digit growth in the last year, and its leading position as one of the fastest…
Polifarma is a Turkish pharma company dedicated to the hospital sector and biosimilars. Its chairman, Ufuk Kumrulu, explains how the company has managed to become a top two company in…
Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer…
The president of the Investment Office of the Presidency of the Republic of Turkey, Burak Dağlıoğlu, outlines the country’s current economic situation after posting the second-highest GDP growth among G20…
Muzaffer Bal, CEO of Ali Raif, a Turkish generics firm, highlights the company’s new investment in a manufacturing plant, their refusal to follow the trend of Turkish local companies investing…
Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies…
Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in biosimilars in collaboration with South Korea’s Genexine and how recent success…
Dr Hamdi Akan, head of Turkey’s Clinical Research Association, dives into the country’s opportunities and barriers to become a clinical trials hub, including the world-class infrastructure and the need for…
İsmail Yormaz, Recordati’s VP and regional director for south-east, highlights how the Milan-based company has become a shining example of a successful localization strategy, upcoming launches and investments, as well…
Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the…
Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire integration has been completed. Atadan discusses how…
TITCK is the regulatory agency in charge of ensuring the safety of medicines, health products, cosmetics, and personal care products in Turkey. Its recently appointed president, Dr Tolga Karakan, discusses…
See our Cookie Privacy Policy Here